In spite of recent progress in revascularization and anesthesiology procedures, in vascular centers today there are still patients with Critical Limb Ischemia (CLI) who are not considered suitable for revascularization. Most of these patients are elderly, with high co-morbidity factors, poor run off arterial limb vessels, and often with a salvageable limb. They are absent or neglected in the literature, and generally go untreated. We report details of 24- month amputations and mortality rates in 90 patients with CLI who were not considered suitable for revascularization, treated from 2005 to 2008 in a dedicated unit of our department. Patients with endstage general conditions or needing immediate primary amputation were excluded from our study. All patients received multidisciplinary assessment. Their median age was 78.4 years; 28 patients (31.1%) had rest pain only, and 62 (68.8%) had ischemic skin foot-leg wounds or gangrene <2 cm. Sixteen patients (37.7%) were assessed as not suitable for revascularization because of poor functional status, and 76 (64.4%) because of inadequate outflow limb vessels. Drugs to manage pain were administered to all patients (100%), prostanoid infusions were given to 80 (88%), anti-platelet drugs to 87 (96%), low molecular weight heparin or oral anticoagulants to 13 (14%), spinal cord stimulation to 3 (3%), hyperbaric oxygen treatment to 16 (17%) and wound treatment to 62 (68.8%). Toe or other foot-sparing amputations had a rate of 13%. After 24 months, the major amputation rate was 9.3% and the mortality rate 23.2%. Our observations show that, in spite of progress in revascularization procedures, there are still patients with CLI who are not considered suitable for revascularization and who could benefit from non-surgical treatment if a tailored approach is used.
Download full-text PDF |
Source |
---|
J Vasc Surg
January 2025
Department of Surgery, Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:
Background: BEST-CLI established the superiority of single-segment great saphenous vein (ssGSV) conduits for revascularization in patients with CLTI; however, the generalizability of these data is unknown. Thus, we aimed to validate the long-term results of open surgical bypass (BPG) versus angioplasty with or without stenting (PTA/S) using the BEST-CLI inclusion and randomization criteria.
Methods: All patients undergoing a first-time lower extremity revascularization for CLTI at our institution from 2005 to 2022 were retrospectively reviewed.
J Clin Med
December 2024
Department of Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland.
Cardiac allograft vasculopathy (CAV) is a major prognosis-limiting factor in patients undergoing orthotopic heart transplantation (HT). Due to the diffuse involvement of the coronary tree, CAV lesions are often not amenable to percutaneous coronary intervention (PCI), leaving coronary artery bypass grafting (CABG) and retransplantation as primary revascularization options. : The latest guidelines from the International Society for Heart and Lung Transplantation (ISHLT) recognize CABG as a viable option but with a downgraded strength of recommendation.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
June 2024
Department of Cardiac Surgery, St Joseph's Health Hospital, Syracuse, New York.
Background: This study compares 2 minimally invasive coronary revascularization approaches: robot-assisted multivessel minimally invasive direct coronary artery bypass (MIDCAB) and the hybrid approach combining MIDCAB with subsequent percutaneous coronary intervention.
Methods: A retrospective review was conducted on cases of robotic MIDCAB performed at our institution between 2012 and 2022. Two groups of patients were analyzed: the surgery group (undergoing robotic multivessel MIDCAB) and the hybrid group.
EuroIntervention
January 2025
Department of Cardiac-Thoracic-Vascular Sciences, University of Padua, Padua, Italy.
This clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions was developed in association with the European Society of Cardiology Working Group on Cardiovascular Surgery. It aims to define procedural and contemporary technical requirements that may improve the efficacy and safety of percutaneous coronary intervention (PCI), both in the acute phase and at long-term follow-up, in a high-risk cohort of patients on optimal medical therapy when clinical and anatomical high-risk criteria are present that entail unacceptable surgical risks, precluding the feasibility of coronary artery bypass grafting (CABG). This document pertains to patients with surgical contraindication according to the Heart Team, in whom medical therapy has failed (e.
View Article and Find Full Text PDFEur Heart J Case Rep
December 2024
Cardiac Electrophysiology and Electrostimulation Unit, San Pietro Fatebenefratelli Hospital Rome, Via Cassia, 600, 00189 Rome, Italy.
Background: The coronary sinus reducer (CSR) is a therapeutic option for patients with coronary artery disease who are not eligible for further revascularization and experience refractory angina. Cardiac resynchronization therapy (CRT) improves symptoms and prognosis in heart failure with reduced ejection fraction, but the presence of a CSR may complicate left ventricular lead placement. Only four cases have been reported so far in this context.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!